 Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC ACCESSWIRE June 14, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today the initiation of its Phase 2 trial of vurolenatide, a proprietary long-acting glucagon-like peptide-1 GLP-1 agonist in adults with short bowel syndrome SBS. Initiating our Phase 2 trial of vurolenatide marks an important milestone for patients and families impacted by the debilitating effects of short bowel syndrome, including chronic diarrhea, said John Temperato, President and Chief Executive Officer of 9 Meters. 